Dr. Feng Ren, Co-CEO and CSO of Insilico Medicine, will attend the 2026 Xiamen Tech Innovation and Securities Industry Development Conference on September 6 (IMAGE)

InSilico Medicine

Dr. Feng Ren, Co-CEO and CSO of Insilico Medicine, will attend the 2026 Xiamen Tech Innovation and Securities Industry Development Conference on September 6

Caption

He will share how Insilico Medicine pushes AI drug discovery from technical validation into clinical translation, detailing how advanced algorithms boost clinical success rates and accelerate commercial value creation for complex disease pipelines.

Credit

Insilico Medicine

Usage Restrictions

None

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.